9 Meters Biopharma NMTR

$ 0.07 -42.97%

Quarterly report 2023-Q1
added 05-15-2023

9 Meters Biopharma Balance Sheet 2011-2024 | NMTR

Annual Balance Sheet 9 Meters Biopharma

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-12.5 M	-46.8 M	-37.8 M	-1.37 M	-532 K	933 K	-1.42 M	4.08 M	4.99 M	788 K	-	-
Long Term Debt	51.4 K	113 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	61.7 K	54.8 K	48.6 K	42.8 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities	30.7 M	8.46 M	6.85 M	14.9 M	10.1 M	2.65 M	3.98 M	-	-	-	-	-
Total Liabilities	30.7 M	8.57 M	7.02 M	14.9 M	10.1 M	2.65 M	3.98 M	10.9 M	11.4 M	2.47 M	-	-
Deferred Revenue	-	-	-	-	-	125 K	1.84 M	1.85 M	-	-	-	-
Retained Earnings	-213 M	-169 M	-	-70.6 M	-43.5 M	-40 M	-32.1 M	-25.9 M	-17.1 M	-6.08 M	-	-
Total Assets	33.1 M	50.2 M	39.2 M	5.3 M	6.45 M	677 K	6.46 M	5.2 M	6.41 M	1.93 M	-	-
Cash and Cash Equivalents	12.6 M	47 M	37.9 M	4.59 M	5.73 M	356 K	1.45 M	119 K	-	-	-	-
Book Value	2.4 M	41.6 M	32.1 M	-9.61 M	-3.66 M	-1.97 M	2.49 M	-5.69 M	-4.99 M	-536 K	-	-
Total Shareholders Equity	2.4 M	41.6 M	32.1 M	-9.61 M	-3.66 M	-12.2 M	2.49 M	-5.69 M	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet 9 Meters Biopharma

	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	34.8 K	51.4 K	15.7 M	83.2 K	98.4 K	113 K	127 K	141 K	155 K	168 K	168 K	168 K	168 K	-	-	14.7 K	29 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	15.6 M	30.7 M	28.7 M	9.42 M	8.32 M	8.57 M	7.41 M	6.86 M	6.14 M	7.02 M	7.02 M	7.02 M	7.02 M	14.9 M	14.9 M	9.63 M	11 M	10.1 M	-	-	10.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-226 M	-213 M	-201 M	-191 M	-180 M	-169 M	-159 M	-146 M	-137 M	-132 M	-132 M	-132 M	-132 M	-70.6 M	-70.6 M	-70.6 M	-70.6 M	-43.5 M	-43.5 M	-43.5 M	-43.5 M	-19.4 M	-19.4 M	-19.4 M	-19.4 M	-32.1 M	-32.1 M	-32.1 M	-32.1 M	-25.9 M	-25.9 M	-25.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	9.31 M	33.1 M	42.1 M	31.5 M	39.3 M	50.2 M	56.7 M	66 M	40.2 M	39.2 M	39.2 M	39.2 M	39.2 M	5.3 M	5.3 M	5.3 M	5.3 M	6.45 M	6.45 M	6.45 M	6.45 M	798 K	798 K	798 K	798 K	6.46 M	6.46 M	6.46 M	6.46 M	4.72 M	4.72 M	4.72 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	6.94 M	12.6 M	15.9 M	29.5 M	37.2 M	47 M	53.6 M	64 M	38.5 M	37.9 M	37.9 M	37.9 M	37.9 M	4.59 M	8.86 M	4.59 M	4.59 M	5.73 M	8.11 M	5.73 M	5.73 M	356 K	356 K	356 K	356 K	361 K	1.45 M	1.45 M	1.45 M	119 K	119 K	119 K	-	97 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-6.3 M	2.4 M	13.5 M	22.1 M	30.9 M	41.6 M	49.3 M	59.1 M	34.1 M	32.1 M	32.1 M	32.1 M	32.1 M	-9.61 M	-9.61 M	-4.34 M	-5.68 M	-3.66 M	6.45 M	6.45 M	-3.66 M	798 K	798 K	798 K	798 K	6.46 M	6.46 M	6.46 M	6.46 M	4.72 M	4.72 M	4.72 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-6.3 M	2.4 M	13.5 M	22.1 M	30.9 M	41.6 M	49.3 M	59.1 M	34.1 M	32.1 M	32.1 M	32.1 M	32.1 M	-9.61 M	-9.61 M	-9.61 M	-9.61 M	-3.66 M	-3.66 M	-3.66 M	-3.66 M	-12.2 M	-12.2 M	-12.2 M	-12.2 M	-6.59 M	2.49 M	2.49 M	2.49 M	-5.69 M	-5.69 M	-5.69 M	-	-4.99 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency